In Focus channel feed

Ra­dio­phar­ma CD­MOs nav­i­gate sup­ply chain, raw ma­te­r­i­al chal­lenges as de­mand goes nu­clear

Last year
Manufacturing

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last year
R&D
Pharma

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

Last year
Deals
R&D

Af­ter years of hype, the first AI-de­signed drugs fall short in the clin­ic

Last year
AI

Most de­tailed hu­man brain map yet is ‘lay­ing the foun­da­tion for find­ing fu­ture cures’

Last year
R&D

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Last year
R&D

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Last year
Discovery

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Last year
Financing
Startups

Dana-Far­ber, Brigham breakup could lead to a rip­ple ef­fect for CGT clin­i­cal tri­als for can­cer

Last year
Cell/Gene Tx

In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

Last year
R&D

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Last year
R&D
Pharma

PacBio, once slat­ed to be ac­quired by Il­lu­mi­na, is tak­ing on the DNA gi­ant

Last year
Diagnostics

In­ver­sa­go was work­ing to­ward a po­ten­tial 2024 IPO, but No­vo’s in­ter­est won out. CB1 biotechs hope to ride the wave

Last year
Deals
Pharma

His tiny pre­na­tal test­ing com­pa­ny has big plans af­ter ex­act­ing le­gal re­venge on lab gi­ants

Last year
R&D
Diagnostics

As Ver­tex’s piv­otal pain read­out looms, non-opi­oid drug de­vel­op­ment faces a reck­on­ing

Last year
R&D

‘This is not a sci­ence prob­lem any­more': Paths emerge for scal­ing up rare dis­ease med­i­cine

Last year
R&D

‘The sleep­ing gi­ant is wak­ing up’: FTC rais­es the pres­sure on phar­ma deal­mak­ing

3 years ago
Deals
Pharma

'Mod­er­na will be a rare dis­ease com­pa­ny,' CEO says, as mR­NA com­pa­ny plots ex­pan­sion in ge­net­ic dis­eases and eyes n-of-1 treat­ments

3 years ago
R&D
Pharma

Es­cap­ing an im­prob­a­ble up­bring­ing, Greg Ver­dine places his biggest ca­reer bets in drug­ging the ‘un­drug­gable’

3 years ago
People

Rich Hor­gan spear­head­ed a gene ther­a­py for his broth­er. The tri­al end­ed in tragedy, but the work con­tin­ues for more pa­tients

3 years ago
Cell/Gene Tx

Fam­i­lies raised mil­lions and hand­ed rare dis­ease ther­a­pies off to biotechs. But com­pa­nies have backed out

3 years ago
R&D

CAR-T re­shaped can­cer treat­ment. Can it change au­toim­mune dis­ease, too?

3 years ago
Cell/Gene Tx

No longer ‘dead or just hi­ber­nat­ing,’ drug­mak­ers re­turn to heart med­i­cines

3 years ago
R&D

Rare dis­ease tri­als can't find enough pa­tients. It's forc­ing the FDA to re­think its ap­proach

3 years ago
FDA+
First page Previous page 1234567 Next page Last page
A service from the Financial Times